| Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. | |
| | |
MedLine Citation:
|
PMID: 20564631 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Imatinib 400 mg daily is the standard treatment for patients with chronic myelogenous leukemia (CML). The safety and efficacy of imatinib in CML patients with pre-existing liver and/or renal dysfunction has not been analyzed. METHODS: The authors analyzed the outcome of 259 patients with early chronic phase CML treated with imatinib (starting dose 400 mg in 50, 800 mg in 209). Pre-existing liver and/or renal dysfunction was seen in 38 (15%) and 11 (4%) patients, respectively. RESULTS: Dose reductions were required in 91 (43%) of 210 patients with normal organ function, compared with 8 (73%) of 11 (P = .065) with renal dysfunction, and 19 (50%) of 38 (P = .271) with liver dysfunction. Grade 3-4 hematologic toxicities including anemia (29%, 10%, and 7% of patients with renal dysfunction, liver dysfunction, and normal organ function, respectively), neutropenia (57%, 30%, and 30%), and thrombocytopenia (43%, 30%, and 26%) were more frequent in patients with pre-existing renal dysfunction treated with high-dose imatinib. Grade 3-4 nonhematologic toxicities were observed at similar frequencies. Complete cytogenetic response rates, event-free survival, and overall survival were similar in all groups. CONCLUSIONS: Although patients with pre-existing liver and/or renal dysfunction might have a higher rate of hematologic toxicity and require more frequent dose reductions, most patients can be adequately managed, resulting in response rates and survival similar to those without pre-existing organ dysfunction. |
| | |
Authors:
|
Wei-Gang Tong; Hagop Kantarjian; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Gautam Borthakur; Jianqin Shan; Sherry Pierce; Mary Beth Rios; Jorge Cortes |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Cancer Volume: 116 ISSN: 0008-543X ISO Abbreviation: Cancer Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-06-24 Completed Date: 2010-07-15 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0374236 Medline TA: Cancer Country: United States |
Other Details:
|
Languages: eng Pagination: 3152-9 Citation Subset: AIM; IM |
Affiliation:
|
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Antineoplastic Agents / adverse effects, therapeutic use* Female Humans Kidney Diseases / complications*, physiopathology Leukemia, Myeloid, Chronic-Phase / complications*, drug therapy*, mortality Liver Diseases / complications*, physiopathology Male Middle Aged Piperazines / administration & dosage, adverse effects, therapeutic use* Protein Kinase Inhibitors / adverse effects, therapeutic use* Pyrimidines / administration & dosage, adverse effects, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Piperazines; 0/Protein Kinase Inhibitors; 0/Pyrimidines; 152459-95-5/imatinib |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Value of integrated positron emission tomography revised using a phantom study to evaluate malignanc...
Next Document: Palliative radiotherapy tailored to life expectancy in end-stage cancer patients: reality or myth?